美国旧金山加利福尼亚大学Soraya Rofagha博士报道，对使用雷珠单抗治疗的患者进行长期随访的结果表明，新生血管(WET)年龄相关性黄斑变性患者在使用抗血管内皮生长因子(VEGF)制剂雷珠单抗治疗的后期，有潜在失明的风险。这可能部分与玻璃体内注射的频率相关。“在很多研究中随访限于1到2年 (ANCHOR, MARINA, EXCITE, SUSTAIN, PrONTO, CATT, IVAN, VIEW), HORIZON是4年，而我们现在做的更久。”她说。

　　PA058

　　Anatomic Correlates of Long-term Visual Outcomes in the ANCHOR/MARINA Cohort of Ranibizumab-Treated AMD Patients

　　Purpose: To report long-term visual and anatomic outcomes of ranibizumab-treated exudative AMD patients from the ANCHOR/MARINA trials with carryover into the HORIZON trial.

　　Methods: Multicenter, uncontrolled, cross-sectional study. Patients were evaluated with ETDRS visual acuity, biomicroscopy, retinal imaging, and genetic analysis.

　　Results: Fifteen sites recruited 65 patients with average follow-up of 7.3 years. Thirty-seven percent of eyes were 20/70 or better. On average, eyes lost 8.6 and 19.8 letters since entry and exit from MARINA/ANCHOR, respectively; 67% had CNV on fluorescein angiography (FA) and 68% had cystoid macular edema and/or SRF on OCT.

　　Conclusion: A minority of eyes had good visual and anatomic outcomes. Most eyes were active by FA and OCT; visual correlates suggest that close follow-up and therapeutic vigilance is necessary.